BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 34879180)

  • 1. Engineered Cell-Derived Vesicles Displaying Targeting Peptide and Functionalized with Nanocarriers for Therapeutic microRNA Delivery to Triple-Negative Breast Cancer in Mice.
    Bose RJ; Kumar US; Garcia-Marques F; Zeng Y; Habte F; McCarthy JR; Pitteri S; Massoud TF; Paulmurugan R
    Adv Healthc Mater; 2022 Mar; 11(5):e2101387. PubMed ID: 34879180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Macrophage-Derived Extracellular Vesicles as Drug Delivery Systems for Triple Negative Breast Cancer (TNBC) Therapy.
    Haney MJ; Zhao Y; Jin YS; Li SM; Bago JR; Klyachko NL; Kabanov AV; Batrakova EV
    J Neuroimmune Pharmacol; 2020 Sep; 15(3):487-500. PubMed ID: 31722094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ultrasound-Guided Microbubble-Mediated Locoregional Delivery of Multiple MicroRNAs Improves Chemotherapy in Hepatocellular Carcinoma.
    Wang H; Hu Z; Sukumar UK; Bose RJ; Telichko A; Dahl JJ; Paulmurugan R
    Nanotheranostics; 2022; 6(1):62-78. PubMed ID: 34976581
    [No Abstract]   [Full Text] [Related]  

  • 4. A Microfluidics-Based Scalable Approach to Generate Extracellular Vesicles with Enhanced Therapeutic MicroRNA Loading for Intranasal Delivery to Mouse Glioblastomas.
    Wang K; Kumar US; Sadeghipour N; Massoud TF; Paulmurugan R
    ACS Nano; 2021 Nov; 15(11):18327-18346. PubMed ID: 34723509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Engineering macrophage-derived exosomes for targeted chemotherapy of triple-negative breast cancer.
    Li S; Wu Y; Ding F; Yang J; Li J; Gao X; Zhang C; Feng J
    Nanoscale; 2020 May; 12(19):10854-10862. PubMed ID: 32396590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adipose-derived mesenchymal stem cells and extracellular vesicles confer antitumor activity in preclinical treatment of breast cancer.
    Li T; Zhou X; Wang J; Liu Z; Han S; Wan L; Sun X; Chen H
    Pharmacol Res; 2020 Jul; 157():104843. PubMed ID: 32360582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A versatile engineered extracellular vesicle platform simultaneously targeting and eliminating senescent stromal cells and tumor cells to promote tumor regression.
    Gong L; Chen Z; Feng K; Luo L; Zhang J; Yuan J; Ren Y; Wang Y; Zheng X; Li Q
    J Nanobiotechnology; 2024 Mar; 22(1):105. PubMed ID: 38468249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of aerobic glycolysis enhances the anti-tumor efficacy of Zoptarelin Doxorubicin in triple-negative breast cancer cells.
    Gründker C; Wokoun U; Hellriegel M; Emons G
    J Obstet Gynaecol Res; 2019 Jul; 45(7):1334-1342. PubMed ID: 31016845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymer nanoparticles mediated codelivery of antimiR-10b and antimiR-21 for achieving triple negative breast cancer therapy.
    Devulapally R; Sekar NM; Sekar TV; Foygel K; Massoud TF; Willmann JK; Paulmurugan R
    ACS Nano; 2015 Mar; 9(3):2290-302. PubMed ID: 25652012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional exosome-mediated co-delivery of doxorubicin and hydrophobically modified microRNA 159 for triple-negative breast cancer therapy.
    Gong C; Tian J; Wang Z; Gao Y; Wu X; Ding X; Qiang L; Li G; Han Z; Yuan Y; Gao S
    J Nanobiotechnology; 2019 Sep; 17(1):93. PubMed ID: 31481080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peptide mediated active targeting and intelligent particle size reduction-mediated enhanced penetrating of fabricated nanoparticles for triple-negative breast cancer treatment.
    Hu G; Chun X; Wang Y; He Q; Gao H
    Oncotarget; 2015 Dec; 6(38):41258-74. PubMed ID: 26517810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymer-Coated Extracellular Vesicles for Selective Codelivery of Chemotherapeutics and siRNA to Cancer Cells.
    Jhan YY; Palou Zuniga G; Singh KA; Gaharwar AK; Alge DL; Bishop CJ
    ACS Appl Bio Mater; 2021 Feb; 4(2):1294-1306. PubMed ID: 35014481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methotrexate-Loaded Extracellular Vesicles Functionalized with Therapeutic and Targeted Peptides for the Treatment of Glioblastoma Multiforme.
    Ye Z; Zhang T; He W; Jin H; Liu C; Yang Z; Ren J
    ACS Appl Mater Interfaces; 2018 Apr; 10(15):12341-12350. PubMed ID: 29564886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surface-engineered extracellular vesicles for targeted delivery of therapeutic RNAs and peptides for cancer therapy.
    Jayasinghe MK; Pirisinu M; Yang Y; Peng B; Pham TT; Lee CY; Tan M; Vu LT; Dang XT; Pham TC; Chen H; Leung AYH; Cho WC; Shi J; Le MT
    Theranostics; 2022; 12(7):3288-3315. PubMed ID: 35547755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual-targeted hybrid nanoparticles of synergistic drugs for treating lung metastases of triple negative breast cancer in mice.
    Zhang T; Prasad P; Cai P; He C; Shan D; Rauth AM; Wu XY
    Acta Pharmacol Sin; 2017 Jun; 38(6):835-847. PubMed ID: 28216624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
    Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
    Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer.
    Deng X; Cao M; Zhang J; Hu K; Yin Z; Zhou Z; Xiao X; Yang Y; Sheng W; Wu Y; Zeng Y
    Biomaterials; 2014 May; 35(14):4333-44. PubMed ID: 24565525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Employing mesenchymal stem cells to support tumor-targeted delivery of extracellular vesicle (EV)-encapsulated microRNA-379.
    O'Brien KP; Khan S; Gilligan KE; Zafar H; Lalor P; Glynn C; O'Flatharta C; Ingoldsby H; Dockery P; De Bhulbh A; Schweber JR; St John K; Leahy M; Murphy JM; Gallagher WM; O'Brien T; Kerin MJ; Dwyer RM
    Oncogene; 2018 Apr; 37(16):2137-2149. PubMed ID: 29367765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo anti-metastatic effects of uPAR retargeted measles virus in syngeneic and xenograft models of mammary cancer.
    Jing Y; Bejarano MT; Zaias J; Merchan JR
    Breast Cancer Res Treat; 2015 Jan; 149(1):99-108. PubMed ID: 25519042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequentially-targeted biomimetic nano drug system for triple-negative breast cancer ablation and lung metastasis inhibition.
    Fan J; Liu B; Long Y; Wang Z; Tong C; Wang W; You P; Liu X
    Acta Biomater; 2020 Sep; 113():554-569. PubMed ID: 32569637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.